только для медицинских специалистов
Консультант врача. Электронная медицинская библиотека

Консультант врача

Электронная медицинская библиотека

Доступ к библиотеке Версия для слабовидящих
Раздел 11 / 16
Страница 1 / 1

Список литературы

  1. Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease / N. Abdel-Wahab, M. Shah, M.A. Lopez-Olivo [et al.] // Ann Intern Med. 2018. Vol. 169. No 2.P. 133-134. 10.7326/l18-0209
  2. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis / R. Barroso-Sousa, W.T. Barry, A.C. Garrido-Castro [et al.] // JAMA Oncol. 2018. Vol. 4. No 2.P. 173-182. 10.1001/jamaoncol.2017.3064
  3. Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis / V. Bergqvist, E. Hertervig, P. Gedeon [et al.] // Cancer Immunol Immunother. 2017. Vol. 66. No 5.P. 581-592. 10.1007/s00262-017-1962-6
  4. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis / A. Bertrand, M. Kostine, T. Barnetche [et al.] // BMC Med. 2015. Vol. 13. 211. 10.1186/s12916-015-0455-8
  5. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline / J.R. Brahmer, C. Lacchetti, B.J. Schneider [et al.] // J Clin Oncol. 2018. Vol. 36. No 17.P. 1714-1768. 10.1200/jco.2017.77.6385
  6. Cancer immunotherapy immune checkpoint blockade and associated endocrinopathies / D.J. Byun, J.D. Wolchok, L.M. Rosenberg [et al.] // Nat Rev Endocrinol. 2017. Vol. 13.No 4.P. 195-207. 10.1038/nrendo.2016.205
  7. Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis / S. Chuzi, F. Tavora, M. Cruz [et al.] // Cancer Manag Res.2017. Vol. 9. 207-213. 10.2147/cmar.s136818
  8. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors / P. Cramer, R.S. Bresalier // Curr Gastroenterol Rep. 2017. Vol. 19. No 1.P. 3. 10.1007/s11894017-0540-6
  9. Population-based assessment of adverse events associated with long-term glucocorticoid use / J.R. Curtis, A.O. Westfall, J. Allison [et al.] // Arthritis Rheum. 2006. Vol. 55. No 3.P. 420-6. 10.1002/art.21984
  10. Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature / S. Cuzzubbo, F. Javeri, M. Tissier [et al.] // Eur J Cancer. 2017. Vol. 73. 18. 10.1016/j.ejca.2016.12.001
  11. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors / E. De Martin, J.M. Michot, B. Papouin [et al.] // J Hepatol. 2018. Vol. 68. No 6.P. 1181-1190. 10.1016/j.jhep.2018.01.033
  12. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia / J.C. Fitzgerald, S.L. Weiss, S.L. Maude [et al.] // Crit Care Med. 2017. Vol. 45. No 2.P. e124-e131. 10.1097/ccm.0000000000002053
  13. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia / N.V. Frey, D.L. Porter // Hematology Am Soc Hematol Educ Program. 2016. Vol. 2016. No 1.P. 567-572. 10.1182/asheducation-2016.1.567
  14. Systematic review: colitis associated with anti-CTLA-4 therapy / A. Gupta, K.M. De Felice, E.V. Loftus, Jr. [et al.] // Aliment Pharmacol Ther. 2015. Vol. 42. No 4.P. 406-17. 10.1111/apt.13281
  15. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity / R. Gutzmer, A. Koop, F. Meier [et al.] // Eur J Cancer. 2017. Vol. 75. 24-32. 10.1016/j.ejca.2016.12.038
  16. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up / J. Haanen, F. Carbonnel, C. Robert [et al.] // Ann Oncol. 2017. Vol. 28. No suppl_4.P. iv119-iv142. 10.1093/annonc/mdx225
  17. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy / K.A. Hay, L.A. Hanafi, D. Li [et al.] // Blood. 2017. Vol. 130. No 21.P. 2295-2306. 10.1182/blood-2017-06-793141
  18. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy / L. Hofmann, A. Forschner, C. Loquai [et al.] // Eur J Cancer. 2016. Vol. 60. 190-209. 10.1016/j.ejca.2016.02.025
  19. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management / B.M. Huffman, L.A. Kottschade, P.S. Kamath [et al.] // Am J Clin Oncol. 2018. Vol. 41. No 8.P. 760-765. 10.1097/coc.0000000000000374
  20. Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders / D.B. Johnson, R.J. Sullivan, P.A. Ott [et al.] // JAMA Oncol. 2016. Vol. 2. No 2.P. 234-40. 10.1001/jamaoncol.2015.4368
  21. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab / R.L. Johnston, J. Lutzky, A. Chodhry [et al.] // Dig Dis Sci. 2009. Vol. 54. No 11.P. 2538-40. 10.1007/s10620-008-0641-z
  22. Tumourand class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review / L. Khoja, D. Day, T. Wei-Wu Chen [et al.] // Ann Oncol. 2017. Vol. 28. No 10.P. 2377-2385. 10.1093/annonc/mdx286
  23. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed DeathLigand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and MetaAnalysis of Trials / M. Khunger, S. Rakshit, V. Pasupuleti [et al.] // Chest. 2017. Vol. 152. No 2.P. 271-281. 10.1016/j.chest.2017.04.177
  24. Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy / V. Kumar, N. Chaudhary, M. Garg [et al.] // Front Pharmacol. 2017. Vol. 8. 49. 10.3389/fphar.2017.00049
  25. Current concepts in the diagnosis and management of cytokine release syndrome / D.W. Lee, R. Gardner, D.L. Porter [et al.] // Blood. 2014. Vol. 124. No 2.P. 188-95. 10.1182/blood-2014-05-552729
  26. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy / M.L. Manzano-Alonso, G. Castellano-Tortajada // World J Gastroenterol. 2011. Vol. 17. No 12.P. 1531-7. 10.3748/wjg.v17.i12. 1531
  27. Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance / A. Mascolo, C. Scavone, C. Ferrajolo [et al.] // Drug Saf. 2021. 10.1007/s40264-021-01086-8
  28. Autoimmune hepatitis / G. Mieli-Vergani, D. Vergani, A.J. Czaja [et al.] // Nat Rev Dis Primers. 2018. Vol. 4. 18017. 10.1038/nrdp.2018.17
  29. Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations / S. Mori, S. Fujiyama // World J Gastroenterol. 2015. Vol. 21. No 36.P. 10274-89. 10.3748/wjg.v21.i36.10274
  30. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis / M. Nishino, A. GiobbieHurder, H. Hatabu [et al.] // JAMA Oncol. 2016. Vol. 2. No 12.P. 1607-1616. 10.1001/jamaoncol.2016.2453
  31. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date / J.H. Park, M.B. Geyer, R.J. Brentjens // Blood. 2016. Vol. 127. No 26.P. 3312-20. 10.1182/blood-2016-02-629063
  32. Cardiotoxicity associated with immune checkpoint inhibitors therapy: A meta-analysis / N. Rubio-Infante, Y.A. Ramírez-Flores, E.C. Castillo [et al.] // Eur J Heart Fail. 2021. 10.1002/ejhf.2289
  33. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy / V. Sibaud // Am J Clin Dermatol. 2018. Vol. 19. No 3.P. 345-361. 10.1007/s40257-017-0336-3
  34. The Risk of Diarrhea and Colitis in Patients With Advanced Melanoma Undergoing Immune Checkpoint Inhibitor Therapy: A Systematic Review and Meta-Analysis / P. Tandon, S. Bourassa-Blanchette, K. Bishay [et al.] // J Immunother. 2018. Vol. 41. No 3.P. 101-108. 10.1097/cji.0000000000000213
  35. Management of Immunotherapy-Related Toxicities, Version 1.2019 / J.A. Thompson, B.J. Schneider, J. Brahmer [et al.] // J Natl Compr Canc Netw. 2019. Vol. 17. No 3.P. 255-289. 10.6004/jnccn.2019.0013
  36. Endocrinological side-effects of immune checkpoint inhibitors / F. Torino, S.M. Corsello, R. Salvatori // Curr Opin Oncol. 2016. Vol. 28. No 4.P. 278-87. 10.1097/cco.0000000000000293
  37. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients / C.J. Turtle, L.A. Hanafi, C. Berger [et al.] // J Clin Invest. 2016. Vol. 126. No 6.P. 212338. 10.1172/jci85309
  38. Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review / R. Wanchoo, S. Karam, N.N. Uppal [et al.] // Am J Nephrol. 2017. Vol. 45. No 2.P. 160-169. 10.1159/000455014
  39. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis / D.Y. Wang, J.E. Salem, J.V. Cohen [et al.] // JAMA Oncol. 2018. Vol. 4. No 12.P. 1721-1728. 10.1001/jamaoncol.2018.3923
  40. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma / J. Weber, J.A. Thompson, O. Hamid [et al.] // Clin Cancer Res. 2009. Vol. 15. No 17.P. 5591-8. 10.1158/1078-0432.ccr09-1024
  41. ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors / A. Yang, S. Baxi, D. Korenstein // J Oncol Pract. 2018. Vol. 14. No 2.P. 72-76. 10.1200/jop.2017.025114
  42. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями / С.А. Проценко, Н.Ю. Антимоник, Л.М. Берштейн [et al.] // Злокачественные опухоли: Практические рекомендации RUSSCO -2018. No 3s2.P. 636–665 -10.18 027 / 2224–5057–2018–8–3s2–636–665
  43. Е.В. Свирщевская, М.Е. В. Сравнительный анализ эффективности и безопасности фторированных и хлорированных топических глюкокортикостероидов. — Москва : РИА "Колизей", 2010. — 76-80.
  44. W.-W. Chen, A. Razak, P. L Bedard [et al.]. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Т. 26, 2015.
  45. Common Terminology Criteria for Adverse Events (CTCAE) Version 5. 2017. — 155.
  46. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management / S. Grover, O.E. Rahma, N. Hashemi [et al.] // American Society of Clinical Oncology Educational Book. 2018. No 38.P. 13-19. 10.1200/edbk_100013
  47. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab / A.M. Menzies, D.B. Johnson, S. Ramanujam [et al.] // Ann Oncol. 2017. Vol. 28. No 2.P. 368-376. 10.1093/annonc/mdw443
  48. NCCN. Management of Immunjtherapy-related toxicities (version 3.2021), 2021. URL: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf (дата обращения: 14.05.2021).
  49. Progress in Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Cardiotoxicity / F. Wang, S. Qin // J Cancer Immunol. 2020. Vol. 2. No 3.P. 96-102.
  50. L. Zimmer, S. Goldinger, L. Hofmann [et al.]. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. 2016.

Для продолжения работы требуется вход / регистрация